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RESEARCH ARTICLE Open Access
Accurate diagnosis of colorectal cancer
based on histopathology images using
artificial intelligence
K. S. Wang1,2†, G. Yu3†, C. Xu4†, X. H. Meng5†, J. Zhou1,2, C. Zheng1,2, Z. Deng1,2, L. Shang1, R. Liu1, S. Su1, X. Zhou1,
Q. Li1, J. Li1, J. Wang1, K. Ma2, J. Qi2, Z. Hu2, P. Tang2, J. Deng6, X. Qiu7, B. Y. Li7, W. D. Shen7, R. P. Quan7, J. T. Yang7,
L. Y. Huang7, Y. Xiao7, Z. C. Yang8, Z. Li9, S. C. Wang10, H. Ren11,12, C. Liang13, W. Guo14, Y. Li14, H. Xiao15, Y. Gu15,
J. P. Yun16, D. Huang17, Z. Song18, X. Fan19, L. Chen20, X. Yan21, Z. Li22, Z. C. Huang3, J. Huang23, J. Luttrell24,
C. Y. Zhang24, W. Zhou25, K. Zhang26, C. Yi27, C. Wu28, H. Shen6,29, Y. P. Wang6,30, H. M. Xiao7* and H. W. Deng6,7,29*
Abstract
Background: Accurate and robust pathological image analysis for colorectal cancer (CRC) diagnosis is time-
consuming and knowledge-intensive, but is essential for CRC patients’ treatment. The current heavy workload of
pathologists in clinics/hospitals may easily lead to unconscious misdiagnosis of CRC based on daily image analyses.
Methods: Based on a state-of-the-art transfer-learned deep convolutional neural network in artificial intelligence
(AI), we proposed a novel patch aggregation strategy for clinic CRC diagnosis using weakly labeled pathological
whole-slide image (WSI) patches. This approach was trained and validated using an unprecedented and
enormously large number of 170,099 patches, > 14,680 WSIs, from > 9631 subjects that covered diverse and
representative clinical cases from multi-independent-sources across China, the USA, and Germany.
Results: Our innovative AI tool consistently and nearly perfectly agreed with (average Kappa statistic 0.896) and
even often better than most of the experienced expert pathologists when tested in diagnosing CRC WSIs from
multicenters. The average area under the receiver operating characteristics curve (AUC) of AI was greater than that
of the pathologists (0.988 vs 0.970) and achieved the best performance among the application of other AI methods
to CRC diagnosis. Our AI-generated heatmap highlights the image regions of cancer tissue/cells.
(Continued on next page)
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Conclusions: This first-ever generalizable AI system can handle large amounts of WSIs consistently and robustly
without potential bias due to fatigue commonly experienced by clinical pathologists. It will drastically alleviate the
heavy clinical burden of daily pathology diagnosis and improve the treatment for CRC patients. This tool is
generalizable to other cancer diagnosis based on image recognition.
Keywords: Colorectal cancer, Histopathology image, Deep learning, Cancer diagnosis
Background
Colorectal cancer (CRC) is the third leading cancer by
incidence (6.1%) but second for mortality (9.2%) world-
wide [1]. The global burden of CRC is expected to in-
crease 60% by 2030, in terms of new cases and deaths
[2]. The accurate and prompt detection of CRC is essen-
tial to improve treatment effectiveness and survivorship.
The current diagnosis of CRC requires an extensive vis-
ual examination by highly specialized pathologists. Diag-
noses are made using digital whole-slide images (WSIs)
of the hematoxylin and eosin (H&E)-stained specimens
obtained from formalin-fixed paraffin-embedded (FFPE)
or frozen tissues. The challenges for the WSI analysis in-
clude very large image size (> 10,000 × 10,000 pixels),
histological variations in size, shape, texture, and stain-
ing of nuclei, making the diagnosis complicated and
time-consuming [3]. In most modern pathology depart-
ments, the average consultative workload increases by ~
5–10% annually [4]. The current trends indicate a short-
age of pathologists around the world, including USA [5]
and low- to middle-income countries [6]. This results in
overworked pathologists, which can lead to higher
chances of deficiencies in their routine work and dys-
functions of the pathology laboratories with more la-
boratory errors [4]. While the demands of colon
specimen examination in gastroenterology clinics are
high, the training time of pathologists is long (> 10 years)
[7]. It is thus imperative to develop reliable tools for
pathological image analysis and CRC detection that can
improve clinical efficiency and efficacy without unin-
tended human bias during diagnosis.
State-of-the-art artificial intelligence (AI) approaches,
such as deep learning (DL), are very powerful in classifi-
cation and prediction. There have been many successful
applications of DL, specifically convolutional neural net-
work (CNN), in WSI analysis for lung [8, 9], breast [10,
11], prostate [12–14], and skin [15, 16] cancers. Most of
the existing CNN for the CRC WSI analysis focused on
the pathology work after cancer determination, including
grade classification [17], tumor cell detection and classi-
fication [18–20], and survivorship prediction [21–23].
Although they resulted in reasonably high accuracy,
their study sample sizes are limited and do not fully rep-
resent the numerous histologic variants of CRC that
have been defined. These variants include tubular,
mucinous, signet ring cell, and others [24]. These limita-
tions inflate prediction error when applied to different
independent samples. Meanwhile, most of the current
DL models were developed from single data source with-
out thorough validation using independent data. They
only calculated the accuracy of patches without diagnos-
ing WSIs or the patients. Their general applicability for
CRC WSI diagnosis in various clinical settings, which
may involve heterogeneous platforms and image proper-
ties, remains unclear. A DL approach generalizable to
daily pathological CRC diagnosis that relieves clinical
burden of pathologists and improves diagnostic accuracy
is yet to be developed [25].
Here, we developed a novel automated AI approach
centered on weakly labeled supervised DL for the very
first general clinical application of CRC diagnosis. This
AI approach uses Inception-v3 CNN architecture [26]
with weights initialized from transfer learning. Weakly
labeled supervised learning is advantageous in training
massive and diverse datasets without exact labelling at
object levels (e.g., small cancer cells) [12]. Transfer
learning is a highly effective and efficient DL technique
for image analysis that can utilize previously learned
knowledge on general images for medical image analyses
[27]. Our work is based on WSIs from multiple inde-
pendent hospitals/sources in China (8554 patients), USA
(1077 patients), and Germany (> 111 slides). This study
has high practical value for improving the effectiveness
and efficiency of CRC diagnosis and thus treatment. It
highlights the general significance and utility of the ap-
plication of AI to image analyses of other types of
cancers.
Methods
Colorectal cancer whole-slide image dataset
We collected 14,234 CRC WSIs from fourteen independ-
ent sources (Table 1). All data were de-identified. The lar-
gest image set was from 6876 patients admitted between
2010 and 2018 in Xiangya Hospital (XH), Central South
University (CSU, Changsha, China). XH is the largest hos-
pital in Hunan Province and was established in 1906 with
a close affiliation with Yale University [28]. The other in-
dependent sources were The Cancer Genome Atlas
(TCGA) of the USA (https://portal.gdc.cancer.gov/) [29],
the National Centre for Tumor Diseases (NCT) biobank
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and the University Medical Center Mannheim
(UMM) pathology archive (NCT-UMM) of Germany
(https://zenodo.org/record/1214456#.XgaR00dTm00,
[22]), Adicon Clinical Laboratories (ACL), INC, and
eleven hospitals in China (detailed in Table 1). The
hospitals involved are located in the major metropol-
itan areas of China serving > 139 million population,
including those most prestigious hospitals in path-
ology in China: XH, Fudan University Shanghai Can-
cer Center (FUS), Chinese PLA General Hospital
(CGH), Southwest Hospital (SWH), and The First
Affiliated Hospital Air Force Medical University
(AMU); other state-level esteemed hospitals: Sun
Yat-Sen University Cancer Center (SYU), Nanjing
Drum Tower Hospital (NJD), Guangdong Provincial
People’s Hospital (GPH), Hunan Provincial People’s
Hospital (HPH), and The Third Xiangya Hospital of
CSU (TXH); and a regional reputable Pingkuang
Collaborative Hospital (PCH). All WSIs were from
FFPE tissues, except parts (~ 75%) of TCGA WSIs
were from frozen tissues [30]. The process of collec-
tion, quality control, and digitalization of the WSIs
is described in Supplementary-Text 1.a (see
Additional file 1).
We formed four datasets (Table 1). Dataset-A includes
slides from only XH and was used for patch-level










Population* CRC Non-CRC Total
Subjects Slides Subjects Slides Subjects Slides
Xiangya Hospital (XH) A FFPE 100% / 0% Changsha,
China
614 614 228 228 842 842
NCT-UMM (NCT-CRC-HE-100 K) B FFPE NA Germany NA NA NA NA NA 86
NCT-UMM (CRC-VAL-HE-7 K) B FFPE NA Germany NA NA NA NA NA 25
XH C FFPE 80% / 20% Changsha,
China
3990 7871 1849 2132 5839 10,
003
XH D FFPE 89% / 11% Changsha,
China
98 99 97 114 195 213
Pingkuang Collaborative Hospital
(PCH)
C & D FFPE 60% / 40% Jiangxi,
China
50 50 46 46 96 96
The Third Xiangya Hospital of CSU
(TXH)
C & D FFPE 61% / 39% Changsha,
China
48 70 48 65 96 135
Hunan Provincial People’s Hospital
(HPH)
C & D FFPE 61% / 39% Changsha,
China
49 50 49 49 98 99
ACL C & D FFPE 22% / 78% Changsha,
China
100 100 107 107 207 207
Fudan University Shanghai Cancer
Center (FUS)
C & D FFPE 97% / 3% Shanghai,
China
100 100 98 98 198 198
Guangdong Provincial People’s
Hospital (GPH)
C & D FFPE 77% / 23% Guangzhou,
China
100 100 85 85 185 185
Nanjing Drum Tower Hospital (NJD) C & D FFPE 96% / 4% Nanjing,
China
100 100 97 97 197 197
Southwest Hospital (SWH) C & D FFPE 93% / 7% Chongqing,
China
99 99 100 100 199 199
The First Affiliated Hospital Air Force
Medical University (AMU)
C & D FFPE 95% / 5% Xi’an, China 101 101 104 104 205 205
Sun Yat-Sen University Cancer Center
(SYU)
C & D FFPE 100% / 0% Guangzhou,
China
91 91 6 6 97 97
Chinese PLA General Hospital (CGH) C FFPE NA Beijing,
China
0 0 100 100 100 100
TCGA (TCGA-Frozen) C Frozen 100% / 0% U.S. 631 1214 110 133 631** 1347
TCGA (TCGA-FFPE) C FFPE 100% / 0% U.S. 441 441 5 5 446 446
Total 6612 11,
100
3129 3469 9631 14,
680
*Location map available in Supplementary Text 1.a (see Additional file 1). **For the TCGA –Frozen data only, the non-CRC slides were made with normal intestinal
tissues on part of the CRC slides
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training and testing (Table 2). We carefully selected
WSIs to include all common tumor histological sub-
types. Using incomplete information of cancer cells/tis-
sues (e.g., location, shape, and demarcation),
pathologists weakly labeled the patches from WSIs as ei-
ther containing or not cancer cells/tissues. Two weakly
labeled patches were provided as illustrative comparative
examples with two fully labeled patches serving as con-
trasts (see Additional file 1: Supplementary-Figure 1).
Patches from the same patient were all put into the same
data set (either training or testing) so that the training
and testing data sets are independent. To ensure an ap-
propriate and comprehensive representation of cancer
and normal tissue characteristics, we included an aver-
age of 49 patches per tumor sample and 144 patches per
healthy sample. The number of patches containing a
large proportion of cancer cells and the number of
patches containing only a few cancer cells were approxi-
mately balanced so that the patches used for training
were representative of cases seen in practice.
Patch-level performance was further validated using
Dataset-B, which contained 107,180 patches downloaded
from NCT-UMM. There were two independent subsets:
100,000 image patches of 86 hematoxylin and eosin stain
(HE) slides of human cancer tissue (NCT-CRC-HE-
100K) and 7180 image patches of 25 slides of CRC tissue
(CRC-VAL-HE-7K) [22]. The overall split for patch-level
training, testing, and external validation was about 2:1:5.
All images are 224 × 224 pixels at 0.5 μm per pixel. More
description can be found at https://zenodo.org/
record/1214456#.XV2cJeg3lhF. The patches were
rescaled to default input size before they are fed to the
networks for testing.
Dataset-C was used for patient-level validation and is
composed of slides from XH, the other hospitals, ACL, and
frozen and FFPE samples of TCGA. Given the high imbal-
ance of cancer and non-cancer slides in SYU and CGH
(Table 1), they were combined in Dataset-C. In Dataset-C,
the area occupied by cancer cells varied in images from dif-
ferent centers. Most (~ 72%) of the slides from the ten hos-
pitals and ACL contained 10–50% cancer cells by area (see
Additional file 1: Supplementary-Figure 2).
Dataset-D was used for the Human-AI contest and
contained approximately equal number of slides from
XH, the other hospitals, and ACL. There is an average of
~ 5045 patches on each slide, and more than 20% of the
slides contain < 1000 patches. Supplementary-Text 1.b
summarized the allocation of slides in the different data-
sets (see Additional file 1).
After the slides were digitalized, the visual verification
of the cancer diagnosis labels was performed with high
stringency and accuracy. Dataset-A and Dataset-C in-
cluded more than 10,000 slides, which were independ-
ently reviewed by two senior and seasoned pathologists
with initial and second read. When their diagnoses were
consistent with the previous clinical diagnosis conclu-
sion, the slides were then included in the dataset. If the
two experts disagreed with each other or with the previ-
ous clinical diagnosis, the slides were excluded. The la-
bels of slides from TCGA were obtained from the
original TCGA database. The labels of Dataset-B were
from the NCT-UMM. The binary labels of Dataset-D for
the Human-AI contest were more strictly checked.
Three highly experienced senior pathologists independ-
ently reviewed the pathological images without knowing
the previous clinical diagnosis. If a consensus was
reached, the slides were included; otherwise, two other
independent pathologists would join the review. After a
discussion among the five pathologists, the sample was
included only if they reached an agreement; otherwise, it
was excluded.
Study design and pipeline
Our approach to predict patient cancerous status in-
volved two major steps: DL prediction for local patches
and patch-level results aggregation for patient-level diag-
nosis (Fig. 1). The WSIs after preprocessing served as
the input for patch-level prediction. A deep-learning
model was constructed to analyze the patches. The
patch-level prediction was then aggregated by a novel
patch-cluster-based approach to provide slide and
patient-level diagnosis. The performance of patch-level
prediction and the way of aggregation would determine
to a large extent the accuracy of patient-level diagnosis.
Our empirical results showed that a patch-level sensitiv-
ity of ~ 95% and specificity of ~ 99% was sufficient to
achieve a high predictive power and control the false
positive rate (FPR) at the patient-level using our
Table 2 Dataset-A (training and testing) and Dataset-B (external validation) for patch-level analysis
Dataset Cancer Non-cancer Total
Subjects Slides Patches Subjects Slides Patches Subjects Slides Patches
Training 406 406 19,940 153 153 22,715 559 559 42,655
Testing 208 208 10,116 75 75 10,148 283 283 20,264
Validation NA NA 15,550 NA NA 91,630 NA 111 107,180*
Total > 614 > 614 45,606 > 228 > 228 124,493 > 842 953 170,099
* There are two datasets used for validation. The number is the sum of the two datasets
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proposed aggregation approach (see Additional file 1:
Supplementary-Text 1.c). In addition, the heatmap and
activation map were generated to show the informative
area on the slide. The details for each step are illustrated
as follows.
Image preprocessing for patch-level training
There were 3 steps in the image preprocessing. First, we
tiled each WSI at × 20 magnification with non-
overlapping 300 × 300 pixel patches, which can be easily
transformed to the required input size of most CNN ar-
chitectures (such as the 299 × 299 input size required by
Inception-v3 [26], see Additional file 1: Supplementary-
Table 1). The use of a smaller patch size compared with
other studies with patches of 512 × 512 pixels would
make the boundaries of cancer regions more accurate
[19]. Second, we removed non-informative background
patches according to two criteria: the maximum differ-
ence among the 3 color channel values of the patch was
less than 20, or the brightness of more than 50% of the
patch surface was less than 220 in grayscale [8]. Com-
bining these two criteria, we removed background
patches and kept as many tissue patches as possible.
Third, regular image augmentation procedures were ap-
plied, such as random flipping and random adjustment
of the saturation, brightness, contrast, and hue. The
color of each pixel was centered by the mean of each
image and its range was converted/normalized from [0,
255] to [− 1, 1].
Patch-level training by deep learning
Our DL model used Inception-v3 as the CNN architec-
ture to classify cancerous and normal patches. The In-
ception network uses different kernel sizes and is
specifically powerful in learning diagnostic information
in pathological image from differing scales. This
architecture has achieved near human expert perform-
ance in the analyses of other cancer types [8, 15, 31, 32].
There are a few Inception architectures performed well
on the ImageNet dataset [33] and WSIs analysis [33],
such as the Inception-v1 [34], Inception-v3 [26], and
Inception-v4 [35]. We chose Inception-v3 based on ex-
tensive comparison of their patch-level and patient-level
performance in testing sets, which showed that the com-
plexity and multiscale modules in Inception-v3 made it
more appropriate to recognize the histopathology WSIs
(see Additional file 1: Supplementary-Text 1.d) [26, 34–
39]. During the study, we also tested some most recent
algorithms, such as DenseNet [37] and ResNeXt [39].
Inception-v3 still performs best at the patch-level CRC
classification.
We initialized the CNN by transfer learning with pre-
trained weights from ImageNet [26], which were opti-
mized to capture the structures in general images [27].
With transfer learning, our model can recognize pivotal
image features for CRC diagnosis most efficiently. The
300 × 300 pixel patches were resized to a size of 299 ×
299 pixels. Accordingly, the patches in the testing sets
were rescaled to 299 × 299 pixels (0.37 μm/pixels) before
they were fed to the network. The network was deeply
fine-tuned by following training steps. Given the possible
high false positive rate after aggregating the patch-level
results, the optimal set of hyper-parameters was ran-
domly searched with an objective of reaching > 95% sen-
sitivity and > 99% specificity. We showed that, with this
objective at the patch level, the error rate at the patient
level was well controlled (see Additional file 1:
Supplementary-Text 1.c). The network was finalized
after 150,000 epochs of fine-tuning the parameters at all
layers using the RMSProp [40] optimizer with a weight
decay of 0.00004, a momentum value of 0.9, and
RMSProp decay set to 0.9. The initial learning rate was
Fig. 1 Study pipeline and dataset usage
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0.01 and was exponentially decayed with epochs to the
final learning rate of 0.0001. The optimized result was
achieved when the batch size was 64. The training and
testing procedures were implemented in a Linux server
with an NVIDIA P100 GPU. We used Python v2.7.15
and Tensorflow v1.8.0 for data preprocessing and CNN
model training and testing.
Patient diagnosis and false positive control
Considering the high false positive rate (FPR) accumu-
lated from multiple patch-level predictions, we proposed
a novel patch-cluster-based aggregation method for
slide-level prediction based on the fact that the tumor
cells tend to gather together (especially at × 20 magnifi-
cation). Motivated by the clustering inference of fMRI
[41], we predicted the WSI as cancer positive if there
were several positive patches topologically connected as
a cluster on the slide (defined by the cluster size), such
as four patches as a square. Otherwise, we predicted the
slide as negative. We tested various cluster sizes and
chose a cluster size of four as the result of an empirically
observed best balance of sensitivity and FPR in the test-
ing dataset (see Additional file 1: Supplementary-Text
1.e). For a patient who had one or multiple slides, de-
noted by S = {s1, s2,…, sl}, we provided the patient-level
diagnosis D(S) combining the results from all of the pa-
tient’s slides: D(S) =D(s1) ∪D(s2) ∪… ∪D(sl), where
D(sl)= 1 or 0 indicated a positive or negative classifica-
tion of the lth slide respectively. The patient will be di-
agnosed as having cancer as long as one of the slides
indicates diagnosis.
Human-AI contest
Six pathologists (A-F) with varying experience of 1 to 18
clinical practice years joined the contest (see Additional
file 1: Supplementary-Table 2). The pathologists inde-
pendently provided a diagnosis specifying cancer or
non-cancer for each patient after reading the WSIs in
Dataset-D. The pathologists did not participate in the
data collection or labeling. An independent analyst
blindly summarized and compared the accuracy and
speed of AI and human experts in performing diagnosis.
Statistical analysis and visualization
We assessed the performance of the AI and patholo-
gists in terms of sensitivity, specificity, and accuracy
(#of correct predictions#of total predictions ) for the diagnosis. The receiver op-
erating characteristic (ROC) curve that plotted the
sensitivity versus the FPR and the corresponding
area under the ROC curve (AUC) were computed.
The AUCs of AI and each of the pathologists in
multiple datasets were compared by the paired Wil-
coxon signed-rank test. We examined the pairwise
agreements among AI and pathologists by Cohen’s
Kappa statistic (K). The statistical analyses were
done in R v3.5 (Vienna, Austria), using packages
caret, ggplot2, pROC, and psych among others. Stat-
istical significance level was set at an alpha level of
0.05.
To locate the CRC region in the WSI, we visualized
the WSI as a heatmap based on the confidence score
of each patch. Brighter regions indicate higher confi-
dence that the classifier would consider the region
cancer positive. The heatmap was generated by Py-
thon (https://www.python.org/) and overlaid with the
original WSI by gimp (https://www.gimp.org/).
Results
Highest accuracies in patch-level prediction by our model
We divided the 842 WSIs from Dataset-A (Table 1) into
62,919 non-overlapping patches (Table 2) to construct
the CNN for patch-level prediction based on fine-tuning
of Inception-v3. An average of ~ 75 patches per WSI
were included to ensure an appropriate and comprehen-
sive representation of cancer and normal tissue charac-
teristics. Three major CRC histological subtypes were
involved for the training and testing, including 74.76%
tubular, 24.59% mucinous, and 0.65% signet ring cell
patches, roughly reflecting their clinical incidences [42].
In the training, 19,940 (46.75%) patches had cancer, and
22,715 (53.25%) patches were normal. Using another in-
dependent set of 10,116 (49.92%) cancer and 10,148
(50.08%) non-cancer patches, the AI for patch-level pre-
diction achieved a testing accuracy of 98.11% and an
AUC of 99.83%. The AUC outperformed that of all the
previous AI studies for CRC diagnosis and prediction
(79.2–99.4%) and even for the majority of other types of
cancer (82.9–99.9%, see Additional file 1:
Supplementary-Tables 3, [8, 12, 17, 19, 22, 43–48]). The
specificity was 99.22% and the sensitivity 96.99%, both
outstanding. In the external validation Dataset-B, our
model yielded an accuracy and AUC of 96.07% and
98.32% in NCT-CRC-HE-100 K, and 94.76% and 98.45%
in CRC-VAL-HE-7 K, which matched the performance
from in-house data and outplayed the patch-level valid-
ation analysis in other AI studies (AUC 69.3–95.0%, see
Additional file 1: Supplementary-Table 3). The patch-
level testing and validation result was summarized in
Table 3.
Diagnosis of CRC at patient level using DL-predicted
patches
Our AI approach was tested for patient diagnosis with
13,514 slides from 8594 patients (Dataset-C). In the lar-
gest subset (5839 patients) from XH, our approach pro-
duced an accuracy of 99.02% and an AUC of 99.16%
(Fig. 2, Table 3). In other independent multicenter
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datasets, our approach consistently performed very well.
For the FFPE slides from other hospitals, TCGA-FFPE,
and ACL, the AI approach yielded an average AUC and
accuracy higher than 97.65% (Fig. 2). For frozen slides
TCGA-Frozen, the AI accuracy and AUC were 93.44%
and 91.05% respectively (Fig. 2). Our AUC values (ran-
ging from 91.05 to 99.16%) were higher than that of
other AI-based approaches for independent datasets
(ranging from 83.3 to 94.1%). Of note, because the ma-
jority of those earlier AI approaches were tested on data-
sets of much smaller sample sizes (see Additional file 1:
Supplementary-Table 3), their performances may be
over-estimated. The limited number of negative slides in
TCGA may result in an imbalanced classification prob-
lem that needs further investigation, which is beyond the
scope of this study. The results on TCGA-Frozen slides
showed that our method did learn the histological
morphology of cancer and normal tissues for cancer
diagnosis, which is preserved in both the FFPE and fro-
zen samples, even though our method was developed
based on the FFPE samples. Table 3 summarized the
complete patient-level result.
Contest with six human experts
The performance of our AI approach was consistently
comparable to the pathologists in diagnosing 1831 WSIs
from independent centers (Dataset-D, Fig. 3). The AI re-
sulted in an average accuracy and AUC of 98.06% (95%
confidence interval [CI] 97.36 to 98.75%) and 98.83%
(95% CI 98.15 to 99.51%), which both ranked top three
out of the seven competitors (AI plus the six
Table 3 Patch-level (Dataset-A and Dataset-B) and patient-level
(Dataset-C and Dataset-D) performance summary
Source Sensitivity Specificity Accuracy AUC
Dataset-A (patch-level testing)
XH 96.99% 99.22% 98.11% 99.83%
Dataset-B (patch-level validation)
NCT-CRC-HE-100 K 92.03% 96.74% 96.07% 98.32%
CRC-VAL-HE-7 K 94.24% 94.87% 94.76% 98.45%
Dataset-C (patient-level validation)
XH 98.80% 99.51% 99.02% 99.16%
TCGA-Frozen 94.04% 88.06% 93.44% 91.05%
TCGA-FFPE 97.96% 100.00% 97.98% 98.98%
SYU-CGH 98.90% 92.45% 95.43% 95.68%
Dataset-D (patient-level Human-AI contest)
XH 97.96% 100% 98.97% 98.99%
SYU 98.90% 100% 98.97% 99.45%
Dataset-C and Dataset-D (patient-level validation and Human-AI
contest)
PCH 96.00% 97.83% 96.88% 97.91%
TXH 100% 97.92% 98.96% 99.20%
HPH 97.96% 97.96% 97.96% 98.98%
FUS 100% 97.96% 98.99% 99.99%
GPH 100% 97.65% 98.91% 99.15%
NJD 92.93% 97.94% 95.41% 95.84%
SWH 98.99% 97.00% 97.99% 99.42%
AMU 97% 97.06% 97.04% 98.37%
ACL 100% 97.20% 98.55% 99.83%
Fig. 2 Patient-level testing performance on twelve independent datasets from Dataset-C. Left: the radar map of the sensitivity, specificity,
accuracy, and AUC in each dataset from Dataset-C. Right: the boxplot showing the distribution of sensitivity, specificity, accuracy, and AUC in
datasets excluding XH and TCGA. The horizontal bar in the box indicates the median, while the cross indicates the mean. Circles represent
data points
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pathologists) and were greater than the average of the
pathologists (accuracy 97.14% (95% CI 96.12 to 98.15%)
and AUC 96.95% (95% CI 95.74 to 98.16%)). The paired
Wilcoxon signed-rank test of AUCs in multicenter data-
sets found there were no significant differences between
AI and each of the pathologists. The AI yielded the high-
est sensitivity (98.16%) relative to the average (97.47%)
of the pathologists (see Additional file 1: Supplementary-
Table 4). The pathologists (D and E) who slightly out-
performed the AI have 7 and 12 years of clinical experi-
ence respectively, while the AI outperformed the other 4
pathologists with 1, 3, 5, and 18 years of experience re-
spectively. Cohen’s Kappa statistic (K) showed an excel-
lent agreement (K ≥ 0.858, average 0.896) between AI
and every pathologist (see Additional file 1:
Supplementary-Table 5). Our approach is thus proven
generalizable to provide diagnosis support for potential
CRC subjects like an independent pathologist, which can
drastically relieve the heavy clinical burden and training
cost of professional pathologists. Details of the Human-
AI contest are given in Supplementary-Tables 4 & 5 (see
Additional file 1)
The pathologists were all informed to compete with
our AI and with each other; hence, their performances
were achieved under their best possible conditions with
very best effort, which represented their highest skill
with least error. However, with heavy workload in clinic,
their performance in terms of accuracy and speed will
not be as stable as that of AI. The current study of AI in
cancer diagnosis using WSI has shown that AI can ac-
curately diagnose in ~ 20 s [8] or less (~ 13 s in our case).
With evolved DL techniques and advanced computing
hardware, the AI can constantly improve and provide
steady, swift, and accurate first diagnosis for CRC or
other cancers.
Slide-level heatmap
Our approach offers an additional distinct feature: heat-
map for highlighting potential cancer regions (as
patches) in WSI. In Fig. 4, we presented two WSIs,
which were overlaid with the predicted heatmap. For
both radical surgery WSI and colonoscopy WSI, the true
cancerous region was highly overlapped with highlighted
patches obtained by AI, which was also verified by pa-
thologists. See more examples in Supplementary-Figure
3 (see Additional file 1). In addition, to visualize inform-
ative regions utilized by DL for the CRC detection, we
provided the activation maps in Supplementary-Figure 4
(see Additional file 1).
Discussion
We collected high-quality, comprehensive, and multiple
independent human WSI datasets for training, testing,
and external validation of our AI-based approach focus-
ing on pathological diagnosis of CRC under common
clinical settings. We mimicked the clinical procedure of
WSI analysis, including the image digitalization, slide re-
view, and expert consultations of the disputed slides.
Fig. 3 ROC analysis of AI and pathologists in the Human-AI contest using Dataset-D. The blue line is the estimated ROC curve for AI. The colored
triangles indicate the sensitivity and specificity achieved by the six pathologists
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Different from other studies [21], we did not apply any
manual selection of slides or the area of interest when
building the study dataset. Given the complex histologic
variants of CRC, we randomly selected training patches
from three most commonly seen subtypes roughly pro-
portional to their incidences. The number of patches
from images with large and small cancer tissue area was
balanced and well represented in patch-level analysis.
The collected images were labeled by agreement of at
least two senior experts in CRC pathology (see Add-
itional file 1: Supplementary-Text 1.b). The testing
dataset from different locations in China, USA, and
Germany served as a representative pool for validation
and generalization. Our dataset well represents the slides
seen in clinics. Consequently, the trained AI model is ro-
bust and generalizable to analyze images of different
production protocols and image quality.
For a fast-growing area, we are aware of that several
new CNN architectures have been proposed after the
completion of the study of the present paper, such as
the DenseNet [37], Squeeze-and-Excitation network
[38], and ResNeXt [39]. We did some exploratory
Fig. 4 Heatmap produced by AI. Top row: WSI from radical surgery (left) and colonoscopy (right); middle row: AI predicted heatmap
corresponding to the first row, with white coloration indicating predicted cancer region; bottom row: heatmap overlaid on the
corresponding WSI
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analysis by comparing the ResNet152V2, DenseNet201,
and NASNetLarge relative to the Inception-v3 in classi-
fying patches. DenseNet201 produced similar evaluation
metrics as Inception-v3, while the other two architec-
tures yielded less accuracy and AUC than Inception-v3.
Although these new models have been shown to in-
crease the prediction accuracy on ImageNet dataset
compared to Inception-v3, the complexity (depth and
number of parameters) and the multiscale modules in
Inception-v3 may be appropriate to recognize the CRC
WSIs. The performance of the new architectures on
pathology images analysis and cancer diagnosis deserves
more focused dedicated research for more detailed tech-
nical comparison. Moreover, we identify other tech-
niques that may extend the current study, such as the
semi- and unsupervised learning [49, 50], which can
learn from more WSIs with and without labels effi-
ciently, and the multiscale decision aggregation and data
augmentation [51], which can work in the presence of
limited data. Given the highly accurate performance
already achieved in the current approach presented, we
can investigate if and how these new techniques might
attain the current prediction performance with less data
collection and labelling effort in future studies.
There are several histological types that were too rare
(less than 0.5% in incidence [52]) to be included, such as
medullary, micropapillary, and serrated. Our AI ap-
proach performed only slightly less satisfactory in frozen
samples than in FFPE samples. With WSIs from rare
types and more frozen samples available for training in
the future, we expect our approach can be constantly
improved to be more generalizable.
Most of the previous studies obtained the patient’s
diagnosis by integrating the patch-level recognition re-
sults, since it is not feasible to process the large-size
WSI directly. This strategy is difficult to control the ac-
cumulated false positive rate (FPR) from multiple predic-
tions based on individual patches. Recently, Coudray
et al. used the proportion of positive patches or the aver-
age probability of all patches as the prediction criterion
for the WSI [8]. Although their results were verified in
three independent datasets (all with small sample sizes
(340 slides)), their aggregation method may not be valid
for those images with only a small area of cancer tissues
where it will yield false negative findings for cancer pa-
tients. Instead, we proposed a novel aggregation strategy
for patch-based WSI or patient-level prediction, which is
intuitive and can easily balance the sensitivity and speci-
ficity. Specifically, we aggregated information from the
cluster of patches that are topologically connected on
the slide to determine the cancer status. In practice, set-
ting the cluster size to four is most likely to exceed the
average accuracy of pathologists, while cluster size of
two can be used for pathological screening with an
average sensitivity of ~ 99.78% and an average specificity
of ~ 72.29% according to our test data (see Additional
file 1: Supplementary-Text 1.e).
Conclusions
In summary, we developed a novel AI-based histopatho-
logical image classification approach for CRC diagnosis
using deep learning, which achieved the best perform-
ance with the largest number of sample sizes and data
sources in the field so far. Our approach was able to
quickly and accurately distinguish CRC cases from
healthy or inflammatory cases and was comparable to or
even superior to pathologists in the testing of large-scale
multicenter data. To the best of our knowledge, this is
the first AI study for a reliable, generalized, and robust
auxiliary tool for daily clinical pathology diagnosis of
CRC initial screening. Our approach may also be
adapted and applied to the histological analysis of other
cancer types via the code available upon request.
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